ETFs
A
ARCT
Arcturus Therape
14.73
+0.75+5.36%After Hours: 14.47 -0.26 -1.77%19:45 09/11 EDT
OPEN/PREV CLOSE14.62/14.73
TODAY RANGE14.42-15.53
VOL596.19K
MARKET CAP434.59M
52 WEEK RANGE5.50-24.17
AVG VOL (3M)866.31K
% TURNOVER1.85%
TURNOVER0
P/E (TTM)-4.6133
% RANGE7.54%
EPS(TTM)-3.3143
P/E(FORWARD)-4.4949
P/B2.529
BVPS6.04
DIVIDEND--
P/S5.30
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP399.88M
SHARES OUTSTANDING28.42M
NEXT EARNINGS11/09-11/13
FREE FLOAT26.15M
LOT SIZE1
EX-DATE11/16/2017
News
Press Releases
Financial Reports
Profile
Benzinga·3d ago
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
TipRanks·4d ago
Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)
TipRanks·09/02 11:40
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
Benzinga·09/01 17:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
Seeking Alpha·08/29 15:00
Broadcom, Palo Alto Networks Headline Earnings Amid A Tight Economic Calendar
Seeking Alpha·08/28 19:00
Catalyst Watch: Jobs report, Cybercab event, and Apple gets a new CEO
Seeking Alpha·08/28 18:08
Arcturus, Moderna fall after BioNTech's cancer vaccine setback
TipRanks·08/26 11:55
Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
TipRanks·08/25 10:32
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium
NASDAQ·08/21 18:09
Arcturus Q2 Loss Widens; ARCT-032 Phase 3 Decision Expected In Q4 2026
Barron‘s·08/21 17:44
Why Moderna's mRNA Cancer Drug Hype Has Gone Too Far
Benzinga·08/21 17:06
12 Health Care Stocks Moving In Friday's Intraday Session
Same Industry
Name/Symbol
Change%
Price